How long does DOB last?

The total duration of DOB via oral is 14 hours to 24 hours. Onset typically occurs within 30 minutes to 1.5 hours. Peak effects last 6 hours to 10 hours.

DOB — SubstanceWiki

DOB (4-bromo-2,5-dimethoxyamphetamine; full name 2,5-dimethoxy-4-bromoamphetamine) is a synthetic psychedelic hallucinogen belonging to the DOx series of substituted amphetamines. First synthesized and characterized by Alexander Shulgin, DOB is among the most potent classical psychedelics in the amphetamine class — active at doses of 1–3 mg — and among the longest-acting, producing experiences of 16–30 hours or more. The duration and potency profile place it at the far extreme of the psychedelic amphetamine series and demand exceptional caution.

DOB's primary use context is as a research tool for studying the 5-HT2 receptor subfamily, where its high selectivity for 5-HT2B makes it pharmacologically distinct from most other psychedelics. In recreational use, its extreme potency creates substantial dosing hazard — active doses are in the microgram-to-low-milligram range, overlapping with the dose range where blotter papers or pressed tablets may be confused with LSD. Multiple poisoning incidents have occurred when DOB-adulterated LSD was unknowingly consumed at doses calibrated for LSD activity.

Harm Reduction

Ehrlich Test for LSD Verification If using blotter papers suspected to be LSD, always use an Ehrlich reagent test. Genuine LSD produces a purple/violet color. No color change indicates absence of an i...

How It Feels

The first indication that DOB has taken hold arrives slowly, almost teasingly. An hour passes after ingestion, then two, and the only clues are a subtle electrical hum in the muscles and a faint metallic taste at the back of the throat. By the third hour, a creeping stimulation has settled into the body, unmistakable and insistent. The heart beats harder and faster than usual. The jaw tightens with a determined clench. There is a building pressure behind the eyes, as if the brain itself were swelling to accommodate something vast. The amphetamine backbone of DOB makes itself known through a driven, restless energy that anchors the entire experience in the body.

As the come-up continues to unfurl, the visual field begins to transform. Colors intensify with an almost aggressive vividness, as though someone has turned the saturation dial far past its natural limit. Geometric patterns emerge not as gentle overlays but as commanding, angular structures. They tile across surfaces with a mechanical precision, intricate and relentless, pulsing in time with the user's heartbeat. There is a sharpness to DOB's visuals that distinguishes them from softer psychedelics. Everything feels etched, heightened, almost too real. Walls, ceilings, and floors may appear to ripple with crystalline grids of impossible intricacy.

At the peak, which can stretch across four to six hours beginning around hour three or four, the stimulation and psychedelia fuse into an experience of sustained intensity. The mind races with ideas that feel both lucid and grandiose. Conversations may take on an exhausting momentum, careening through topics with manic energy. Emotionally, there is a volatility that mirrors the physical drive: euphoria, awe, irritability, and paranoia can all surface within the same hour. Body temperature regulation becomes unreliable, and fluctuations between sweating and chills are common. The pupils are widely dilated, and peripheral vasoconstriction may cause the fingers and toes to feel cold or tingling, even as the core runs hot.

The descent from DOB is one of its most defining and, for many, most punishing features. The experience does not simply end after six or eight hours. Instead, it tapers with agonizing slowness across another six to twelve hours, sometimes longer. The stimulation persists long after the psychedelic intensity has faded, leaving a wired, hollowed-out restlessness that resists sleep. The jaw remains sore. The body feels like a machine that has been running at redline for too long. When sleep finally comes, it arrives heavy and dreamless, and the following day is often marked by a dull, depleted fatigue that lingers into the evening.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(10)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(17)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...

Detection Methods

Urine Detection

DOB (4-bromo-2,5-dimethoxyamphetamine) is an amphetamine-derived psychedelic with a long duration of action and corresponding extended detection window. Due to its structural relationship to amphetamine, DOB and its metabolites may trigger presumptive positive results on standard amphetamine immunoassays. Urine detection windows are estimated at 2 to 4 days following ingestion when analyzed by immunoassay, and potentially longer with LC-MS/MS methods. The extended duration of action (up to 20 hours or more) means the body is eliminating parent compound and metabolites over a prolonged period.

Blood and Serum Detection

Blood detection windows for DOB are approximately 12 to 36 hours after oral ingestion, reflecting the compound's long pharmacological half-life. Peak plasma concentrations occur 2 to 4 hours post-ingestion. The slow offset of effects correlates with sustained measurable blood concentrations. LC-MS/MS provides the most sensitive and specific blood analysis.

Standard Drug Panel Inclusion

DOB is NOT specifically listed on standard 5-panel, 10-panel, or 12-panel drug screens. However, unlike most psychedelics, DOx-series amphetamines may cross-react with amphetamine immunoassays due to their intact amphetamine backbone. A presumptive positive for amphetamine on initial screening is a realistic possibility. On confirmatory testing by GC-MS or LC-MS/MS, the result would not confirm as amphetamine or methamphetamine, and would be reported as negative unless the laboratory specifically includes DOx compounds in their confirmatory panel. Most routine clinical laboratories do not test for DOx amphetamines.

Confirmatory Methods

Definitive identification of DOB requires GC-MS or LC-MS/MS with reference standards specific to DOx compounds. The amphetamine backbone makes GC-MS analysis straightforward without derivatization in most cases. Some forensic toxicology laboratories include DOx amphetamines in extended novel psychoactive substance panels. The relatively long detection window compared to other psychedelics provides a larger sampling window for confirmatory testing.

Reagent Testing (Harm Reduction)

The Marquis reagent produces variable color reactions with DOx amphetamines, ranging from orange-brown to olive-green depending on the specific compound. The Mecke reagent may produce blue-green to brown reactions. The Mandelin reagent typically shows green to brown. Critically, the Ehrlich reagent shows NO reaction with DOx amphetamines, which distinguishes them from lysergamides and tryptamines. Because DOx compounds are sometimes sold on blotter paper mimicking LSD, the Ehrlich test is an essential safety tool: absence of a purple reaction on blotter strongly suggests the substance is not LSD and may be a DOx compound or NBOMe. Given the very long duration of DOx compounds (12-24+ hours), correct identification prior to ingestion is important for safety planning.

Interactions

Substance	Status	Note
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabis	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Toxicity & Safety

Extreme Duration as a Toxicological Factor

The 16–30 hour duration dramatically amplifies every risk dimension. Cardiovascular stress from amphetamine-like stimulation persists for an extraordinarily long time. Behavioral impairment — impaired judgment, potentially dangerous actions — extends through a full day and night cycle. Sleep deprivation is essentially guaranteed. Post-experience fatigue and psychological vulnerability persist into the following day.

Vasoconstriction and Peripheral Ischemia

DOb and related DOx compounds are associated with significant vasoconstriction. At high doses, severe peripheral vasoconstriction can cause tissue hypoperfusion, similar to ergotamine toxicity, with reported cases of peripheral ischemia. This is a rare but serious physical toxicity not commonly seen with indole psychedelics.

Cardiovascular Strain

Amphetamine-type cardiovascular stimulation (tachycardia, hypertension, vasoconstriction) sustained for 16–30 hours represents substantial risk for individuals with cardiovascular vulnerabilities. Even in healthy individuals, the duration represents an unusual cardiac burden.

Acute Poisoning Events

The greatest documented harm from DOB arises from dose confusion with LSD. Blotter papers sold as LSD containing DOB have produced poisoning events — users who ingest multiple "blotters" assuming LSD potency receive multiple times the active DOB dose, producing overwhelming 24–30+ hour experiences with severe physiological toxicity, including vasoconstriction requiring medical intervention.

Drug Interactions

MAOIs — potentiated toxicity; absolute contraindication
Stimulants — compounded cardiovascular strain over the multi-hour duration
Cannabis — may dramatically intensify and prolong already extreme experience

Addiction Potential

not habit-forming

Overdose Information

Overdose

Internationally, DOB is a Schedule I drug under the Convention on Psychotropic Substances.

Australia: DOB is listed as a Schedule II substance in Australia.
Austria: DOB is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Canada: DOB is listed as a Schedule 1 as it is an analogue of amphetamine.
Germany: DOB is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of September 1, 1984. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: DOB is a Schedule I controlled substance.
The Netherlands: DOB is a Lijst 1 substance, making it a harddrug.
New Zealand: DOB is Schedule I (Class A) in New Zealand. DOB would also qualify as an analogue under New Zealand's catch-all analogues section in Schedule 3 / Class C of their drug laws which would make 2C-I, 2C-E, DOI, DOB, ephedrine and pseudoephedrine Schedule 3 compounds in the country.
Poland: DOB is controlled in Poland.
Romania: DOB is a controlled substance, classified as a high-risk drug.
Switzerland: DOB is a controlled substance specifically named under Verzeichnis D.
United Kingdom: DOB is Schedule I/Class A in the U.K., making it illegal to sell, buy, or possess without a license.
United States: DOB is Schedule I in the U.S., making it illegal to sell, buy, gift, produce or possess without a DEA license.
Responsible use
Research chemical
Substituted amphetamine
Phenethylamine
DOx
DOC
DOM
2C-B
DOB (Wikipedia)
DOB (Erowid Vault)
DOB (PiHKAL / Isomer Design)
Discussion
The Big & Dandy DOB Thread (Bluelight)

Full	almost immediately after ingestion
Half	4-7 days
Zero	7-10 days

DOB

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(10)

Tactile(1)

Cognitive & Perceptual Effects

Visual(17)

Pharmacology

Mechanism of Action

Prodrug Possibility

Pharmacokinetics

Stimulant Component

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Shulgin Synthesis

Research Use

Adulteration History

Legal Status

Harm Reduction

Ehrlich Test for LSD Verification

Dose Guidelines

Duration Planning

Emergency Preparedness

Avoiding Confusion with LSD

Toxicity & Safety

Extreme Duration as a Toxicological Factor

Vasoconstriction and Peripheral Ischemia

Cardiovascular Strain

Acute Poisoning Events

Drug Interactions

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (7)

Community Discussions (1)

See Also

Similar by Effects

Same Class

References (6)

Frequently Asked Questions

Cognitive(17)

Multi-sensory(1)

Transpersonal(3)